Drug Y officially landed in Jiahui International Cancer Center and became a pioneer in the use of dual immunotherapy in China

Shanghai, October 12, 2021/PRNewswire/ - On June 10, 2021, the first CTLA-4 inhibitor ipilimumab in China was approved by the China National Medical Products Administration (NMPA) to join Navuriu Monoclonal antibody (Nivolumab, trade name Opdivo, commonly known as O drug) is used for the first-line treatment of patients with newly treated, unresectable, non-epithelioid malignant pleural mesothelioma [1], which means "Y drug + O drug" dual immunity The combination therapy for the treatment of pleural mesothelioma was officially approved in China

Immune Gemini opens a new pattern in the treatment of malignant pleural mesothelioma

Malignant Pleural Mesothelioma (MPM) is a rare tumor derived from pleural mesothelial cells.

The "Y drug + O drug combination treatment plan" was confirmed in a multi-center, open-label, randomized phase III clinical trial (CheckMate 743) study: Compared with standard chemotherapy (platinum combined with pemetrexed), this Combined treatment of previously untreated patients with unresectable MPM, the median overall survival (mOS) was extended by 4 months (18.

In the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Clinical Application of Immune Checkpoint Inhibitors (2021 Edition)", nivolumab combined with ipilimumab for the first-line treatment of non-epithelial and epithelioid pleural mesothelioma became the only one to obtain I Level (1 type of evidence) and II level of recommendation (2A type of evidence) treatment plan [4]

One step ahead, Jiahui provides Y medicine services for domestic patients

As the first and only approved CTLA-4 inhibitor in China, drug Y mainly inhibits the combination of CTLA-4 of activated T cells and B7 of antigen-presenting cells, breaking immune tolerance and enhancing T cell activity [5]

PD-1 inhibitor nivolumab (drug O) combined with CTLA-4 inhibitor ipilimumab (drug Y) is considered to have a potential synergistic mechanism: drug Y helps activate and proliferate T cells, while drug O The drug helps existing T cells to find tumors.

Whether it is the malignant pleural mesothelioma that has been approved in China or more indications approved by the FDA, the combination of Y drugs and "Y drugs + O drugs" has shown the potential to bring long-term survival benefits to cancer patients

As a tumor immunotherapy demonstration center established in a non-public hospital, Jiahui International Cancer Center (Jiahui International Cancer Center) strives to shorten the time for drug approval and procurement at the beginning of the approval of the Y drug.

Jiahui International Oncology Center takes "frontier, standard, and safe" as its diagnosis and treatment purpose, has a professional and strong team strength, and has rich experience in immunotherapy and drug safety management

Reference materials:

[1] https:// Chinese Medical Doctor Association Multidisciplinary Tumor Diagnosis and Treatment Professional Committee.

[3]Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D , Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.

[4] "Guidelines for Clinical Application of Immune Checkpoint Inhibitors" 2021 CSCO Guidelines

[5] He Jie "Introduction to Oncology" 2nd Edition, People's Medical Publishing House

Source: Jiahui Medical